Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

por Soubeyran, I., Quénel, N., Mauriac, L., Durand, M., Bonichon, F., Coindre J-M
Publicado 1996

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

por Soubeyran, I., Quénel, N., Coindre, J. M., Bonichon, F., Durand, M., Wafflart, J., Mauriac, L.
Publicado 1996